Sandoz TV Episode 18: Trailer
Find out what to expect from the newest episode of Sandoz TV.
|Global News||Sandoz Around the World||Sandoz in the Media|
FDA approves Sandoz Erelzi™ to treat multiple inflammatory diseases
Holzkirchen, Germany, August 30, 2016
Sandoz, a Novartis division and the global leader in biosimilars, announced today that the US Food and Drug Administration (FDA) approved Erelzi (etanercept-szzs) for all indications included in the reference product label
Launch of novel on-demand news service Transplant TODAY from TTS 2016 transplant congress
Holzkirchen, August 09, 2016
Sandoz today announces the launch of a novel online medical education platform, Transplant TODAY, offering access to latest news from the 26th International Congress of The Transplantation Society (TTS2016).
Novartis Second Quarter 2016 Results
Basel, July 19, 2016
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
Keep Data in Biosimilar Labeling Clear
Holzkirchen, July 15, 2016
In an op-ed published last week Carlos Sattler, MD, Vice President of Clinical Development and Medical Affairs, emphasized the need for a regulatory environment that creates a level playing field for biosimilars.
Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases
Holzkirchen, July 13, 2016
Sandoz, a Novartis division and leader in biosimilars, announced today that the US Food and Drug Administration (FDA) Arthritis Advisory Committee recommended approval of its proposed biosimilar etanercept